COMP <GO>
MDLN vs UNH // EV/EBITDA & P/E VALUATION
Medline Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: MDLN 4
— UNH 8
▲ EV/EBITDA & P/E VALUATION LEADER: UNH
LAST: $32.00 (-1.14%) • MKT CAP: $42.07B
valuation
20.3x
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
valuation
16.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDLN VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDLN | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.57% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.20% | 11.47% | -3.27 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 20.3x | 16.4x | +3.85 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 3.08% | 6.48% | -3.40 | UNH | /fcf-yield <GO> |
| Operating Margin | 7.80% | 4.82% | +2.98 | MDLN | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 3.14% | +64.86 | MDLN | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 6.46% | +5.04 | MDLN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.50 | 3.12 | -0.62 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 59.2 | -28.30 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 0.33 | +0.78 | MDLN | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.07B | $368.83B | -$326.76B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDLN REV | UNH REV | MDLN GROSS % | UNH GROSS % | MDLN FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $28.43B | $447.57B | 26.4% | 88.7% | $1.30B | $16.07B |
| FY 2024 | $25.51B | $400.28B | 27.3% | 88.3% | $1.42B | $20.70B |
| FY 2023 | $23.23B | $371.62B | — | 89.6% | $639.6M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDLN // BETA 1.11
UNH // BETA 0.33